Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression

Hideki Murata, Koji Yoshimoto, Ryusuke Hatae, Yojiro Akagi, Masahiro Mizoguchi, Nobuhiro Hata, Daisuke Kuga, Akira Nakamizo, Toshiyuki Amano, Tetsuro Sayama, Koji Iihara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Proneural and mesenchymal are two subtypes of glioblastoma identified by gene expression profiling. In this study, the primary aim was to detect markers to develop a clinically applicable method for distinguishing proneural and mesenchymal glioblastoma. The secondary aims were to investigate the temporospatial dynamics of these markers and to explore the association between these markers and the expression of chromatin-modifying genes. One hundred thirty-three glioma samples (grade II: 14 samples, grade III: 18, grade IV: 101) were analyzed. We quantified the expression of 6 signature genes associated with proneural and mesenchymal glioblastoma by quantitative reverse transcription-polymerase chain reaction. We assigned proneural (PN) and mesenchymal (MES) scores based on the average of the 6 markers and calculated a predominant metagene (P-M) score by subtracting the MES from the PN score. We used these scores to analyze correlations with malignant transformation, tumor recurrence, tumor heterogeneity, chromatin-modifying gene expression, and HDAC7 expression. The MES score positively correlated with tumor grade, whereas the PN score did not. The P-M score was able to distinguish the proneural and mesenchymal subtypes. It was decreased in cases of tumor recurrence and malignant transformation and showed variability within a tumor, suggesting intratumoral heterogeneity. The PN score correlated with the expression of multiple histone-modifying genes, whereas the MES score was associated only with HDAC7 expression. Thus, we demonstrated a simple and straightforward method of quantifying proneural/mesenchymal markers in glioblastoma. Of note, HDAC7 expression might be a novel therapeutic target in glioblastoma treatment.

Original languageEnglish
Pages (from-to)33-41
Number of pages9
JournalJournal of Neuro-Oncology
Volume125
Issue number1
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Glioblastoma
Chromatin
Gene Expression
Neoplasms
Recurrence
Gene Expression Profiling
Transcriptome
Glioma
Histones
Genes
Reverse Transcription
Polymerase Chain Reaction
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Detection of proneural/mesenchymal marker expression in glioblastoma : temporospatial dynamics and association with chromatin-modifying gene expression. / Murata, Hideki; Yoshimoto, Koji; Hatae, Ryusuke; Akagi, Yojiro; Mizoguchi, Masahiro; Hata, Nobuhiro; Kuga, Daisuke; Nakamizo, Akira; Amano, Toshiyuki; Sayama, Tetsuro; Iihara, Koji.

In: Journal of Neuro-Oncology, Vol. 125, No. 1, 01.10.2015, p. 33-41.

Research output: Contribution to journalArticle

@article{f054d946584f4df086c75385255f4b9e,
title = "Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression",
abstract = "Proneural and mesenchymal are two subtypes of glioblastoma identified by gene expression profiling. In this study, the primary aim was to detect markers to develop a clinically applicable method for distinguishing proneural and mesenchymal glioblastoma. The secondary aims were to investigate the temporospatial dynamics of these markers and to explore the association between these markers and the expression of chromatin-modifying genes. One hundred thirty-three glioma samples (grade II: 14 samples, grade III: 18, grade IV: 101) were analyzed. We quantified the expression of 6 signature genes associated with proneural and mesenchymal glioblastoma by quantitative reverse transcription-polymerase chain reaction. We assigned proneural (PN) and mesenchymal (MES) scores based on the average of the 6 markers and calculated a predominant metagene (P-M) score by subtracting the MES from the PN score. We used these scores to analyze correlations with malignant transformation, tumor recurrence, tumor heterogeneity, chromatin-modifying gene expression, and HDAC7 expression. The MES score positively correlated with tumor grade, whereas the PN score did not. The P-M score was able to distinguish the proneural and mesenchymal subtypes. It was decreased in cases of tumor recurrence and malignant transformation and showed variability within a tumor, suggesting intratumoral heterogeneity. The PN score correlated with the expression of multiple histone-modifying genes, whereas the MES score was associated only with HDAC7 expression. Thus, we demonstrated a simple and straightforward method of quantifying proneural/mesenchymal markers in glioblastoma. Of note, HDAC7 expression might be a novel therapeutic target in glioblastoma treatment.",
author = "Hideki Murata and Koji Yoshimoto and Ryusuke Hatae and Yojiro Akagi and Masahiro Mizoguchi and Nobuhiro Hata and Daisuke Kuga and Akira Nakamizo and Toshiyuki Amano and Tetsuro Sayama and Koji Iihara",
year = "2015",
month = "10",
day = "1",
doi = "10.1007/s11060-015-1886-y",
language = "English",
volume = "125",
pages = "33--41",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Detection of proneural/mesenchymal marker expression in glioblastoma

T2 - temporospatial dynamics and association with chromatin-modifying gene expression

AU - Murata, Hideki

AU - Yoshimoto, Koji

AU - Hatae, Ryusuke

AU - Akagi, Yojiro

AU - Mizoguchi, Masahiro

AU - Hata, Nobuhiro

AU - Kuga, Daisuke

AU - Nakamizo, Akira

AU - Amano, Toshiyuki

AU - Sayama, Tetsuro

AU - Iihara, Koji

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Proneural and mesenchymal are two subtypes of glioblastoma identified by gene expression profiling. In this study, the primary aim was to detect markers to develop a clinically applicable method for distinguishing proneural and mesenchymal glioblastoma. The secondary aims were to investigate the temporospatial dynamics of these markers and to explore the association between these markers and the expression of chromatin-modifying genes. One hundred thirty-three glioma samples (grade II: 14 samples, grade III: 18, grade IV: 101) were analyzed. We quantified the expression of 6 signature genes associated with proneural and mesenchymal glioblastoma by quantitative reverse transcription-polymerase chain reaction. We assigned proneural (PN) and mesenchymal (MES) scores based on the average of the 6 markers and calculated a predominant metagene (P-M) score by subtracting the MES from the PN score. We used these scores to analyze correlations with malignant transformation, tumor recurrence, tumor heterogeneity, chromatin-modifying gene expression, and HDAC7 expression. The MES score positively correlated with tumor grade, whereas the PN score did not. The P-M score was able to distinguish the proneural and mesenchymal subtypes. It was decreased in cases of tumor recurrence and malignant transformation and showed variability within a tumor, suggesting intratumoral heterogeneity. The PN score correlated with the expression of multiple histone-modifying genes, whereas the MES score was associated only with HDAC7 expression. Thus, we demonstrated a simple and straightforward method of quantifying proneural/mesenchymal markers in glioblastoma. Of note, HDAC7 expression might be a novel therapeutic target in glioblastoma treatment.

AB - Proneural and mesenchymal are two subtypes of glioblastoma identified by gene expression profiling. In this study, the primary aim was to detect markers to develop a clinically applicable method for distinguishing proneural and mesenchymal glioblastoma. The secondary aims were to investigate the temporospatial dynamics of these markers and to explore the association between these markers and the expression of chromatin-modifying genes. One hundred thirty-three glioma samples (grade II: 14 samples, grade III: 18, grade IV: 101) were analyzed. We quantified the expression of 6 signature genes associated with proneural and mesenchymal glioblastoma by quantitative reverse transcription-polymerase chain reaction. We assigned proneural (PN) and mesenchymal (MES) scores based on the average of the 6 markers and calculated a predominant metagene (P-M) score by subtracting the MES from the PN score. We used these scores to analyze correlations with malignant transformation, tumor recurrence, tumor heterogeneity, chromatin-modifying gene expression, and HDAC7 expression. The MES score positively correlated with tumor grade, whereas the PN score did not. The P-M score was able to distinguish the proneural and mesenchymal subtypes. It was decreased in cases of tumor recurrence and malignant transformation and showed variability within a tumor, suggesting intratumoral heterogeneity. The PN score correlated with the expression of multiple histone-modifying genes, whereas the MES score was associated only with HDAC7 expression. Thus, we demonstrated a simple and straightforward method of quantifying proneural/mesenchymal markers in glioblastoma. Of note, HDAC7 expression might be a novel therapeutic target in glioblastoma treatment.

UR - http://www.scopus.com/inward/record.url?scp=84942986528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942986528&partnerID=8YFLogxK

U2 - 10.1007/s11060-015-1886-y

DO - 10.1007/s11060-015-1886-y

M3 - Article

C2 - 26272600

AN - SCOPUS:84942986528

VL - 125

SP - 33

EP - 41

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -